Cullen/Frost Bankers, Inc. Biomarin Pharmaceutical Inc Transaction History
Cullen/Frost Bankers, Inc.
- $6.83 Billion
- Q2 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 13 shares of BMRN stock, worth $917. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13Holding current value
$917% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding BMRN
# of Institutions
632Shares Held
185MCall Options Held
1.63MPut Options Held
1.2M-
Black Rock Inc. New York, NY22.7MShares$1.6 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.34 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA18.8MShares$1.33 Billion1.14% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$983 Million0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.69MShares$684 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $13.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...